US drug maker Eli Lilly plans to launch its weight-loss drugs Zepbound and Mounjaro in India next year. The company is considering pricing based on supply and volume expansion. Eli Lilly CEO David Ricks suggests focusing on digital services in the Indian healthcare industry to encourage innovation and improve access to healthcare.
At a market cap that exceeds $720 billion, US drug maker Eli Lilly tops the list of worlds most valuable pharmaceutical companies. The key to that is recent US approval for its weight-loss drug Zepbound (tirzepatide).